Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: AgAuUSA who wrote (9215)	5/6/1998 10:54:00 PM
From: Scott H. Davis	Respond to of 14328

No, they're not meaningless. Learning market psychology is another good investing discipline. As I said in a post earlier today, ISIP and VICL went up too soon too high on a major news item. ENMD is not ready for clinical trials yet. No way I would touch them in 98. VICL is close to break even, has a nicely rounding out pipeline with a lot of key collaborations, with the cash reserves and low burn rate to pull it off. ISIP just filed an NDA and the euro equivilent, and has a number of other compounds in clinical trials. LGND will have at least 2 NDA's this year and is projected to be profitable next year (.47 is current estimate of 4 analysts) Every two weeks, I collect prices on over 100 mutual funds, devided up into funds focusing on particular market segments and visciplines (6 small cap value growth funds, 5 large cap growth, financial, medical, tech and energy sector funds, Europe, SE Asia..) In order to keep pulse on where the market is going - what works and what is not currently. So yes, I do consider market psychology important. I used to pick stocks on the basis of "neat and cool stuff" Learned the hard way. The first group of three stocks were picks due to their balance sheets, value + growth characteristics, and the stregnth of product (Networking stocks that is) The biotechs were picked according to where they are in the clinical development stage, big pharma endorsements (following heavy DD you can be sure) and where they are in the risk/reward curve. There really was some method in my madness. Scott